Loading quotes...

Forecast

The analysts' average price target is €589.87 (-0.59%). The median is €611.43 (+3.04%).

Buy
  4
Hold
  15
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

Financials

In the last quarter, Medpace had revenue of €632.12m and net profit of €121.36m
(EUR) September 2026
YoY
Revenue 632.12m 12.41%
Gross profit 197.66m 17.78%
Net profit 121.36m 28.15%
EBITDA 156.69m 22.68%

Fundamentals

Metric Value
Market capitalization
€16.62bn
Number of shares
27.97m
52-week high/low
€630.48 - €338.87
Dividends No
Beta
1.12
P/E ratio
35.62
PEG ratio
1.41
P/B ratio
31.24
P/S ratio
6.44

Company profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Name
Medpace
CEO
August James Troendle
Headquarters Cincinnati, oh
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
11/08/2016
Employees 6,600

Ticker symbols

Exchange Symbol
NASDAQ
MEDP
Frankfurt
01P.F
DĂĽsseldorf
01P.DU
MĂĽnchen
01P.MU
🍪

Parqet  uses cookies. Learn more